Analyst reports.

This information is provided for information purposes only. The opinions, estimates, forecasts or any analysis do not represent the opinions, forecasts, or any analysis of our Company or management or staff. We do not by its reference imply any concurrence with the independently provided opinions, estimates or forecasts.

Analyst Reports 2024

Analyst Reports 2024
November 14th 2024

Baird - INSIGHT-003 Data Adds Support for Efti in NSCLC Ahead of Phase 3; Rated OP, US$7 PT (Analyst: Joel L. Beatty, MD)

For a copy of this research report please contact your Baird advisor

November 14th 2024

Maxim - Positive Survival Data for Efti Triple Combo in 1L NSCLC; Bodes Well for Upcoming P3 Pivotal TACTI-004 Study in Same Setting - Rated Buy, US$12 PT (Analyst: Jason McCarthy, Ph.D.)

For a copy of this analyst report please contact your Maxim advisor

November 14th 2024

CLSA - Checking-off key points; Positive survival data in triple combo incrementally derisk TACTI-004; Maintain Outperform, A$0.95 PT (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor

November 14th 2024

Bell Potter - Lung cancer Phase 1 trial: Strong data update; Maintain Buy, A$0.70 PT (Analyst: Thomas Wakim)

For a copy of this research report please contact your Bell Potter advisor

November 14th 2024

Wilsons - INSIGHT-003 | Flexing in 1L NSCLC; Maintain Overweight, A$1.05 PT (Analyst: Dr Shane Storey)

October 21st 2024

Maxim - P1 Study of IMP761 Moves to Dose Escalation Portion of Trial; Watching for Updates Around Three Core Efti Programs; Rated Buy, US$12 PT (Analyst: Jason McCarthy, Ph.D.)

For a copy of this analyst report please contact your Maxim advisor

September 25th 2024

Canaccord Genuity - Upcoming FDA ODAC meeting puts mounting pressure on Keytruda; Buy, A$0.95 PT (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor

September 19th 2024

Capital One - Head and Neck Expert Call – Key Takeaways; Reiterate OW; US$8 PT (Analyst: Naureen Quibria, PhD)

For a copy of this research report please contact your Capital One advisor

September 16th 2024

Canaccord Genuity - ESMO update: HNSCC update an incremental positive; Rated Buy, A$0.95 PT (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor

September 16th 2024

Capital One - Incremental Update on Cohort A (TACTI-003) at ESMO; KOL Call Tomorrow; Rated OW; US$8 PT (Analyst: Naureen Quibria, PhD)

For a copy of this research report please contact your Capital One advisor

September 16th 2024

Bell Potter - No Major Revelations from ESMO Data; Maintain Buy, A$0.70 PT (Analyst: Thomas Wakim)

For a copy of this research report please contact your Bell Potter advisor

September 15th 2024

Baird - Update on Efti in HNSCC at ESMO; We Continue to View NSCLC as Top Setting; Maintain OP, US$6 PT (Analyst: Joel L. Beatty, MD)

For a copy of this research report please contact your Baird advisor

September 15th 2024

Wilsons - ESMO updates; Maintain Overweight, A$1.05 PT (Analysts: Dr Melissa Benson and Dr Shane Storey)

September 15th 2024

CLSA - ESMO 2024-HNSCC presentation highlights favourable trends in efti + Keytruda; Rated Outperform, A$0.95 PT (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor

September 11th 2024

Capital One - Exciting HARMONi-2 Data at WCLC Shouldn’t Discount Efti/Pembro Combo in NSCLC; Reiterate OW; $8 PT (Analyst: Naureen Quibria, PhD)

For a copy of this research report please contact your Capital One advisor

September 11th 2024

CLSA - Head & neck take two: Hopeful on durability data at ESMO, may support positive outlook; Retain Outperform, A$0.95 PT (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor

September 9th 2024

Wilsons - Summit data relevance limited; Maintain Overweight, A$1.05 PT (Analysts: Dr Melissa Benson and Dr Shane Storey)

September 3rd 2024

Capital One - IMMP Reports FY24: ESMO Update on TACTI-003 (HNSCC, CPS>1) on 9/15; Rated OW; $8 PT (Analyst: Naureen Quibria, PhD)

For a copy of this research report please contact your Capital One advisor

August 30th 2024

Jefferies - FY24: Adventure of a Lifetime; Buy, A$1.10 PT (Analyst: Dr David Stanton)

For a copy of this research report please contact your Jefferies advisor

August 23rd 2024

Bell Potter - Looking out for two LAG-3 ESMO Presentations; Maintain Buy, A$0.75 PT (Analyst: Thomas Wakim)

For a copy of this research report please contact your Bell Potter advisor

August 16th 2024

Canaccord Genuity - IMM highlights efti's unique mechanism and upcoming news flow at CG Growth Conference; Maintain Buy, A$0.95 PT (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor

August 1st 2024

Ladenburg Thalmann - Moving Forward and Onward; Reaffirm Buy, US$8.30 PT (Analyst: Ahu Demir, PhD)

For a copy of this research report please contact your Ladenburg Thalmann advisor

July 25th 2024

Wilsons - Next steps for Efti in HNSCC; Maintain Overweight, A$1.05 PT (Analysts: Dr Melissa Benson and Dr Shane Storey)

July 16th 2024

Capital One - IMMP: Takeaways from our KOL Call on TACTI-003; Rated OW; $8 PT (Analyst: Naureen Quibria, PhD)

For a copy of this research report please contact your Capital One advisor

July 15th 2024

Bell Potter - TACTI-003 Cohort B Update; Maintain Buy, A$0.75 (Analyst: Thomas Wakim)

For a copy of this research report please contact your Bell Potter advisor

July 12th 2024

Canaccord Genuity - Efti continues to impress in CPS<1 HNSCC patients; Maintain Buy, A$0.95 PT (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor

July 12th 2024

Maxim - Positive Response Data for Efti + Keytruda in 1L H&N Cancer, Cohort B; Reiterate Buy, US$12 PT (Analyst: Jason McCarthy, Ph.D.)

For a copy of this analyst report please contact your Maxim advisor

July 12th 2024

Ladenburg Thalmann - Efti is Making Keytruda Work in PD-L1 Negative Patients in Head and Cancer; Rated Buy, US$8.30 PT (Analyst: Ahu Demir, PhD)

For a copy of this research report please contact your Ladenburg Thalmann advisor

July 12th 2024

CLSA - Heating up; Positive head & neck PD-1 negative readout highlights opportunity; Maintain BUY, A$0.95 PT and O-PF rating retained (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor

July 11th 2024

Baird - Efti in Combo With Keytruda Shows Encouraging 35% ORR in 1L HNSCC; Maintain OP, US$6 PT (Analyst: Joel L. Beatty, MD)

For a copy of this research report please contact your Baird advisor

July 11th 2024

Jefferies - Phase 2B 1L HNSCC update – ORR in CPS <1 improves c9%; Buy, A$0.93 PT (Analyst: Dr David Stanton)

For a copy of this research report please contact your Jefferies advisor

June 28th 2024

Bell Potter - Combo data supportive in HNSCC; Retain Buy, A$0.75 (Analyst: Thomas Wakim)

For a copy of this research report please contact your Bell Potter advisor

June 28th 2024

Canaccord Genuity - Headstrong conviction in Efti's potential clinical impact; Maintain Buy, A$0.95 PT (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor

June 28th 2024

Wilsons - TACTI-003 download: take a pause; Maintain Overweight, A$1.13 PT (Analysts: Dr Melissa Benson and Dr Shane Storey)

June 27th 2024

Maxim - An Imbalance in the 1L H&N Control Arm Data but the Overall Efti + Keytruda Combo is Positive and Consistent; Reiterate Buy, $12 PT (Analyst: Jason McCarthy, Ph.D.)

For a copy of this analyst report please contact your Maxim advisor

June 27th 2024

Ladenburg Thalmann - Our Thoughts on TACTI-003 Data; Reaffirm Buy, $8.30 PT (Analyst: Ahu Demir, PhD)

For a copy of this research report please contact your Ladenburg Thalmann advisor

June 27th 2024

Capital One - IMMP: Cohort Imbalance Muddies Cohort A Topline Data, But Could Still Improve; Rated OW; $10 PT (Analyst: Naureen Quibria, PhD)

For a copy of this research report please contact your Capital One advisor

June 27th 2024

CLSA - TACTI-003: Cohort A data; Cohort A delivers a ‘pass’ mark, but patient imbalances cloud comparison; Retain BUY, A$0.95 PT (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor

June 27th 2024

Baird - Efti Shows Favorable Trend on ORR in Phase 2b Trial in HNSCC; Maintain OP, $6 PT (Analyst: Joel L. Beatty, MD)

For a copy of this research report please contact your Baird advisor

June 27th 2024

Wilsons - Immutep Limited (IMM) | TACTI-003: the real results; Maintain Overweight, A$1.13 PT (Analysts: Dr Melissa Benson and Dr Shane Storey)

June 17th 2024

Capital One - IMMP: TACTI-004 Design Unveiled; Investor Focus Is on 1L HNSCC Data; Rated OW; $10 PT (Analyst: Naureen Quibria, PhD)

For a copy of this research report please contact your Capital One advisor

June 12th 2024

Maxim - Is Efti the Answer for Merck's Keytruda Franchise? Going to P3 in 1L Lung is a Big Deal; Maintain Buy, Raise PT to $12 (Analyst: Jason McCarthy, Ph.D.)

For a copy of this analyst report please contact your Maxim advisor

June 6th 2024

Baird - Collab with Merck Provides Downside Support Ahead of Phase 2 HNSCC Data; Maintain OP, $7 PT (Analyst: Joel L. Beatty, MD)

For a copy of this research report please contact your Baird advisor

June 5th 2024

CLSA - Cap raise strengthens position; A$100m raise reduces sentiment risk ahead of key readout; Retain BUY, A$0.95 PT (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor

May 17th 2024

Capital One - IMMP: No LAG(gard) Here, Efti’s Ready to Go Pivotal; Initiating at OW, $10 PT (Analyst: Naureen Quibria, PhD)

For a copy of this research report please contact your Capital One advisor

May 16th 2024

CLSA - Higher dosing showing promise; MBC efti+chemo dose escalation complete response, no safety concerns; Rated BUY, A$0.95 (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor

May 15th 2024

Canaccord Genuity - Efti poster at ESMO: Continued safety is a win; Rated Buy, A$1 Price Target (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor

May 3rd 2024

Bell Potter - More Great Data, Major Catalyst Nears; Maintain Buy, A$0.80 Valuation (Analyst: Thomas Wakim)

For a copy of this research report please contact your Bell Potter advisor

May 2nd 2024

Canaccord Genuity - Ticking all the boxes - initial positive read from efti in soft tissue sarcoma; Rated Buy, A$1 Price Target (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor

April 30th 2024

Ladenburg Thalmann - 3Q FY2024: Bullish on Randomized Trial Readout; Reaffirm Buy, $8.30 PT (Analyst: Ahu Demir, PhD)

For a copy of this research report please contact your Ladenburg Thalmann advisor

April 29th 2024

Canaccord Genuity - Not LAG-ing Behind in the Immune Oncology Race; Initiating Coverage with a BUY Rating and A$1 tgt (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor

April 24th 2024

Ladenburg Thalmann - TACTI-003 Interim Readout: Boosting Confidence in Head and Neck; Reaffirm Buy, $8.30 PT (Analyst: Ahu Demir, PhD)

For a copy of this research report please contact your Ladenburg Thalmann advisor

April 24th 2024

Maxim Group - Preliminary Data from TACTI-003 Outperforms Historical Control by 5x; Full ORR Data Expected Within C2Q24; Mtn Buy, $10 tgt (Jason McCarthy, PhD)

For a copy of this analyst report please contact your Maxim advisor

April 24th 2024

Baird - Encouraged by Efti Topline Results in PD-L1 Negative Head and Neck Cancer; Rated Outperform, $7 tgt (Analyst: Joel L. Beatty, MD, CFA)

For a copy of this research report please contact your Baird advisor

April 24th 2024

CLSA - 1L Head & Neck Cohort B ORR 5x higher vs Keytruda monotherapy; Response rate encouraging in difficult to treat patients, surprises to the upside (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor

April 24th 2024

Jefferies - efti/pembro 5x ORR increase over pembro monoRx (Analyst: Dr David Stanton)

For a copy of this research report please contact your Jefferies advisor

April 24th 2024

Bell Potter - Exceptional first taste of TACTI-003 data, 27% ORR ~5x higher than historical ORR of ~5%; Maintain Buy and increase Price Target to A$0.80 (Analyst: Thomas Wakim)

For a copy of this research report please contact your Bell Potter advisor

April 24th 2024

Wilsons - Efti boosts Keytruda response 5x; Maintain Overweight, A$1.04 tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)

April 19th 2024

Ladenburg Thalmann - Autoimmune Program is Advancing into Clinic; Reaffirm Buy, $8.30 PT (Analyst: Ahu Demir, PhD)

For a copy of this research report please contact your Ladenburg Thalmann advisor

April 18th 2024

Wilsons - Adding Autoimmune to the indication list; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)

April 4th 2024

Bell Potter - Thoughts Ahead of TACTI-003 Readout; Maintain Buy, A$0.65 tgt (Analyst: Thomas Wakim)

For a copy of this research report please contact your Bell Potter advisor

March 27th 2024

CLSA - Checking in; Maintain Buy, A$0.95 tgt (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor

March 6th 2024

Ladenburg Thalmann - Next Is Dose Optimization for BC Program; Reiterate Buy, $8.30 PT (Analyst: Ahu Demir, PhD)

For a copy of this research report please contact your Ladenburg Thalmann advisor

March 6th 2024

Baird - First Data on Highest Dose Ever of Efti Includes a Complete Response; Rated Outperform, $7 tgt (Analyst: Joel L. Beatty, MD, CFA)

For a copy of this research report please contact your Baird advisor

March 5th 2024

Wilsons - Dose it higher? Now an option; Mtn Overweight, A$0.90 Tgt (Analysts: Dr Melissa Benson and Dr Shane Storey)

March 5th 2024

CLSA - Nearing the Checkpoint; Upcoming HNSCC trial readout & Ph3 NSCLC progress key focus in CY24; Mtn Buy, A$0.95 Tgt (Analyst: Andrew Paine)

For a copy of this research report please contact your CLSA advisor

March 4th 2024

Bell Potter - Multiple Indications Advancing; Maintain Buy, Raise tgt to A$0.65 (Analyst: Thomas Wakim)

For a copy of this research report please contact your Bell Potter advisor

February 29th 2024

Ladenburg Thalmann - Eyes Are on Controlled Study (TACTI-003) Results; Reaffirm Buy, $8.30 PT (Analyst: Ahu Demir, PhD)

For a copy of this research report please contact your Ladenburg Thalmann advisor

February 26th 2024

goetzpartners securities - Efti MoA strong durable in multiple cancers; Reit Buy, A$2.74 tgt (Analyst: Dr Chris Redhead)

This research report is intended for use only by persons who qualify as professional investors or eligible counterparties (institutional investors) in the applicable jurisdiction, and not by any private individuals or other persons who qualify as retail clients.